Sunday 11 October 2026 Export all LLY data to Excel Powerpack

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,179.27 9.67 +0.83%
Market cap
$1.10T
P/E
39.6×
Fwd P/E
33.1×
Dividend yield
0.57%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
9 8 7 8

+8 more TTM periods

ROE
102.29% 107.46% 101.16% 96.47%
ROA
21.97% 24.54% 21.59% 19.33%
ROIC
26.33% 30.18% 26.61% 25.82%
Return on Tangible Assets
57.79% 56.50% 45.79% 41.61%
Average Days of Receivables
107.56 106.99 112.87 119.52
Free Cash Flow per Share
20.38 13.22 10.00 10.34
Free Cash Flow
18,190.00 11,823.00 8,972.00 9,271.80
Other line items

Show all line items

Columns are period end dates